Financial Performance Highlights

  • Revenue from Operations: Increased to ₹4,657.46 lakh in FY 2025-26 from ₹2,455.77 lakh in FY 2024-25, representing growth of approximately 89.65%
  • Profit After Tax: Increased to ₹461.99 lakh from ₹309.96 lakh in the preceding financial year, representing growth of approximately 49.05%
  • EBITDA: Stood at ₹750.32 lakh compared to ₹475.70 lakh in previous year
  • Total Expenditure: Increased to ₹4,033.35 lakh from ₹2,044.13 lakh
  • Finance Costs: Increased to ₹72.06 lakh from ₹29.66 lakh
  • Depreciation: Increased to ₹40.80 lakh from ₹26.34 lakh

Capital Structure Changes

  • Paid-up Share Capital: Stood at ₹6,86,00,000 comprising 68,60,000 equity shares of ₹10 each as of 31 March 2026
  • IPO Completion: Successfully completed maiden Initial Public Offering comprising fresh issue of 18,60,000 equity shares of ₹10 each at issue price of ₹70 per share (including securities premium of ₹60 per share), aggregating ₹1,302.00 lakh
  • Listing: Equity shares listed on BSE SME Platform with effect from 30 September 2025
  • Bonus Issue: Post year-end, allotted 1,02,90,000 fully paid-up bonus equity shares in ratio of three bonus shares for every two existing shares, increasing paid-up capital from ₹6.86 crore to ₹17.15 crore

Business Operations and Strategy

  • Product Portfolio: Expanded from over 140 products as at 31 March 2023 to over 194 products as at 31 March 2025 and further to over 250 products as at 31 March 2026
  • Business Verticals:
  • Pharma Formulations (core revenue-generating business)
  • Consumer Products (developing consumer healthcare, wellness and personal-care brands)
  • International Business (overseas opportunities through domestic merchant exporters)
  • Asset-light Model: Partners with WHO-GMP certified manufacturers for quality, scalability and efficiency

Corporate Developments Post Financial Year End

  • Bonus Issue: Approved through Postal Ballot concluded on 25 April 2026, shares allotted on 12 May 2026
  • Preferential Allotment Proposal: Board approved on 17 August 2026 proposal to issue up to 16,02,870 equity shares of ₹10 each at issue price of ₹280 per share (including premium of ₹270 per share), aggregating approximately ₹44.88 crore

Preferential Issue Details

  • Purpose: Strengthen capital base for capital expenditure (₹25.00 crore), working capital requirements (₹10.00 crore), and general corporate purposes (₹9.88 crore)
  • Allottees: 190 proposed allottees including individuals, corporate entities, HUFs and LLPs
  • Price Determination: Floor price of ₹280 per share determined as per SEBI ICDR Regulations based on 10-day VWAP
  • Lock-in: Subject to lock-in as per Chapter V of SEBI ICDR Regulations
  • Post-issue Shareholding: Promoter holding expected to reduce from 72.89% to 67.18%

Annual General Meeting Details

  • Date: 14 September 2026 at 11:00 AM IST
  • Mode: Video Conferencing/Other Audio-Visual Means
  • Business:
  • Ordinary Business: Adoption of financial statements and appointment of director liable to retire by rotation
  • Special Business: Approval of preferential allotment of equity shares

Corporate Governance

  • Board Composition: 6 directors including 2 independent directors
  • Board Meetings: 11 meetings held during FY 2025-26
  • Committees: Audit Committee, Nomination and Remuneration Committee, Stakeholder Relationship Committee, Internal Complaints Committee
  • Auditors:
  • Statutory Auditors: M/s A B K B & Co., Chartered Accountants
  • Secretarial Auditors: M/s. JPMK & Associates, Practising Company Secretaries

Utilization of IPO Proceeds

As of 31 March 2026, full utilization of ₹1,302.00 lakh raised through IPO:

  • Capital expenditure for office premises: ₹162.95 lakh
  • Working capital requirements: ₹800.00 lakh
  • General corporate purposes: ₹191.05 lakh
  • IPO related expenses: ₹148.00 lakh

Forward-looking Statements

The document contains forward-looking statements subject to various risks and uncertainties including fluctuations in earnings, ability to manage growth, competition, changes in input costs, market conditions, technological developments, and regulatory changes.